Moderna to present Phase 3 melanoma vaccine data on Oct 24, sparking share rally
Moderna announced that it will present additional Phase 3 trial results for its personalized melanoma vaccine, developed with Merck, at the European Society for Medical Oncology Congress on Oct 24. The news has lifted the stock, which has risen about 38% since late September and 4.5% on the day of the announcement. Analysts note the trial involved 1,137 patients and met its primary endpoint of reducing cancer recurrence. Barclays projects the therapy could generate roughly $3 billion in annual melanoma sales by 2035, split equally between Moderna and Merck.
Why it matters
Barclays estimates the vaccine could produce about $3 billion of annual melanoma sales by 2035, indicating a potential new revenue stream for Moderna. The upcoming data release may further move the share price as investors assess the efficacy and commercial prospects.
Key facts
- 1Moderna will present additional Phase 3 trial data for its melanoma vaccine on Oct 24 at the European Society for Medical Oncology Congress. tradingview.com
- 2The Phase 3 study enrolled 1,137 patients and met its primary endpoint of reducing cancer recurrence. tipranks.com
- 3Moderna's shares have risen about 38% since late September ahead of the data presentation. gurufocus.com
- 4The stock gained roughly 4.5% on the day of the announcement. tipranks.com
- 5Barclays estimates the treatment could generate roughly $3 billion in annual melanoma sales by 2035, split equally with Merck. tipranks.com
- 6Moderna reported a Q2 net loss of $782 million and cash and investments of $6.9 billion at the end of June. tipranks.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.